China Taiwan Crises
Type 1 Diabetes Market

Type 1 Diabetes Market Size, Share & Segment by Product Type (Januvia, Humalog, Lantus, Novorapid, Galvus, Humalin), by End User (Specialty Centers, Hospitals & Clinics), and by Regions | Global Market Forecast 2022-2028

Report Id: SNS/HC/1076 | May 2022 | Region: Global | 125 Pages

Report Scope & Overview:

The Type 1 Diabetes Market Size was valued at USD 7.06 billion in 2021, and is expected to reach USD 11.79 billion by 2028, and grow at a CAGR of 7.6% over the forecast period 2022-2028. People can develop one of two forms of diabetes. Type 1 diabetes now accounts for 10 percent of all diabetes cases worldwide.

People get this type of diabetes when their bodies don't generate enough insulin or don't produce enough insulin to handle all of the refined and other types of sugars they consume every day! Obese young people are more likely to develop type 1 diabetes. What makes matters worse for people with type 1 diabetes is that they will age quickly. As individuals get older, they tend to embrace unhealthy behaviors. This motivates those with type 1 diabetes to stick with it.

Type 1 Diabetes Market

MARKET DYNAMICS

DRIVERS

  • Increased acceptance of Western diets

  • lifestyles that promote high-fat eating

  • Less exercise

  • Short - long Term Damage

RESTRAINTS

  • These medications are effective in managing type 1 diabetes

  • They can have unpleasant and even hazardous side effects.

OPPORTUNITIES

  • Pharmaceutical businesses have benefited from the profitable market.

  • More Development and research in medicines

CHALLENGES

  • Expensive medication

  • Medicines will face in the near and long term is ensuring that newer generations of drugs are safer.

IMPACT OF COVID-19

The year before, COVID-19 proven to be a serious infection. Until early this year, there's no vaccine for it. The virus was contained by governments implementing short quarantines and indefinite lockdowns. Those who did not test positive for COVID-19 suffered the repercussions.

Individuals with other illnesses, including as diabetes and cancer, were unable to receive medical care when they required it since many doctors and other health providers refused to visit patients who did not have life-threatening illnesses. Many persons with Type 1 diabetes were fatally ill or died as a result of this delay

 COMPETITIVE LANDSCAPE

Abbott Laboratories, Bayer AG, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd, Merck & C0., Pfizer Inc., Takeda Pharmaceutical, AstraZeneca PLC., XOMA Corp, and others.

KEY MARKET SEGMENT:

By Product Type

  • Januvia

  • Humalog

  • Lantus

  • Novorapid

  • Galvus

  • Humalin

By End User

  • Specialty Centers

  • Hospitals & Clinics

Type 1 Diabetes Market

REGIONAL ANALYSIS

Corporations and governments in the Asia-Pacific area are stepping in to help diabetics who might otherwise be unable to buy or obtain various treatments.

The European Union has the second-largest market share for type 1 diabetes. This is largely due to the fact that an increasing number of Europeans are moving away from their historically healthy diets and lives and toward less healthy American diets and lifestyles.

REGIONAL COVERAGE:

North America

  • USA

  • Canada

  • Mexico

Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe

Asia-Pacific

  • Japan

  • South Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of Middle East & Africa

Latin America

  • Brazil

  • Argentina

  • Rest of Latin America

 

Type 1 Diabetes Market Report Scope:
Report Attributes Details
Market Size in 2021 US$ 7.06 Billion
Market Size by 2028 US$ 11.79 Billion
CAGR CAGR of 7.6% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product Type (Januvia, Humalog, Lantus, Novorapid, Galvus, Humalin)
• By End User (Specialty Centers, Hospitals & Clinics)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Abbott Laboratories, Bayer AG, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd, Merck & C0., Pfizer Inc., Takeda Pharmaceutical, AstraZeneca PLC., XOMA Corp, and others.
DRIVERS • Increased acceptance of Western diets
• lifestyles that promote high-fat eating
• Less exercise
RESTRAINTS • These medications are effective in managing type 1 diabetes
• They can have unpleasant and even hazardous side effects.


Frequently Asked Questions (FAQ) :

People get this type of diabetes when their bodies don't generate enough insulin or don't produce enough insulin to handle all of the refined and other types of sugars, they consume every day! Obese young people are more likely to develop type 1 diabetes

Key drivers of the Type 1 Diabetes Market are the Increased acceptance of Western diets and lifestyles that promote high-fat eating

Januvia, Humalog, Lantus, Novorapid, Galvus, and Humulin are the sub segments by product type.

Top-down, bottom-up, Quantitative, Qualitative Research, Descriptive, Analytical, Applied, and Fundamental Research.

Type 1 Diabetes Market Size was valued at USD 7.06 billion in 2021, and is expected to reach USD 11.79 billion by 2028, and grow at a CAGR of 7.6% over the forecast period 2022-2028.


Table of Contents


1. Introduction
1.1 Market Definition 
1.2 Scope
1.3 Research Assumptions
 
2. Research Methodology
 
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
 
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Ukraine ware

5. Value Chain Analysis
 
6. Porter’s 5 forces model
 
7.  PEST Analysis
  
8. Type 1 Diabetes Market Segmentation, by Product Type
8.1    Januvia
8.2    Humalog
8.3     Lantus
8.4    Novorapid
8.5      Galvus
  8.6     Humalin

9.  Type 1 Diabetes Market Segmentation, by End User
9.1    Specialty Centers
9.2    Hospitals & Clinics

10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 USA
10.2.2 Canada
10.2.3 Mexico
10.3    Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 The Netherlands
10.3.7 Rest of Europe
10.4    Asia-Pacific
10.4.1 Japan
10.4.2 South Korea
10.4.3 China
10.4.4 India
10.4.5 Australia
10.4.6 Rest of Asia-Pacific
10.5    The Middle East & Africa
10.5.1 Israel
10.5.2 UAE
10.5.3 South Africa
10.5.4 Rest
10.6    Latin America
10.6.1 Brazil
10.6.2 Argentina
10.6.3 Rest of Latin America

11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Financial
11.1.2 Products/ Services Offered
11.1.3 SWOT Analysis
11.1.4 The SNS view
11.2 Bayer AG
11.3 Eli Lilly and Company
11.4 GlaxoSmithKline
11.5 Johnson & Johnson Ltd
11.6 Merck & C0.
11.7 Pfizer Inc.
11.8 Takeda Pharmaceutical
11.9 AstraZeneca PLC.
11.10 XOMA Corp

12. Competitive Landscape
12.1 Competitive Benchmark
12.2 Market Share analysis
12.3 Recent Developments

13. Conclusion

 

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of a good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach a stage wherein we can provide our clients best and most accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research as the name suggests is a research process wherein, we collect data through readily available information. In this process, we use various paid and unpaid databases to which our team has access and gather data through the same. This includes examining listed companies’ annual reports, Journals, SEC filling, etc. Apart from this, our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various universities as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content-specific facts that can be sued to solve specific problems. Since the collected data is fresh and first-hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply sides of the industry to make sure we land an accurate judgment and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses, and observation of on-field participants. The below-mentioned chart should give a better understanding of part 1 of the primary interview.

Part 2: In this part of the primary research the data collected via secondary research and part 1 of the primary research is validated with the interviews with individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence center, our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real-time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but is not limited to getting rid of the many typos, duplication of numbers, or missing any important information. The people involved in this process include technical content writers, research heads, and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.